Bristol-Myers Squibb (BMY) Stock

$53.90 -2.07 (-3.70%)
Market Cap: $109.32B | NYSE

Bristol-Myers Squibb Chart


Company Profile

Price: $53.90

Market Cap: $109.32B

Exchange: NYSE

CEO: Dr. Christopher S. Boerner Ph.D.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 34.10K

Headquarters: New York, NY

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb News

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial.

News image

BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.

News image

What's Going On With Bristol Myers Squibb Stock On Monday?

Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

News image

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

News image

Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a recent share price decline, BMY's strategic cost reductions, debt repayments, and dividend commitments highlight its long-term growth and shareholder return focus. LOE risks for key drugs like Yervoy and Eliquis and cautious 2025 guidance suggest temporary volatility, justifying a "Hold" rating at the current share price.

News image

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

News image

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focuses on developing a 'growth portfolio' and pipeline execution, with promising approvals like subcutaneous Opdivo and Cobenfy. Despite significant debt and uncertainty, Bristol-Myers is a compelling contrarian buy if pipeline execution offsets the $25B at-risk revenue from patent expirations.

News image

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

News image

Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so quickly.

News image

Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript

Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2024 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Chris Shibutani - Goldman Sachs Tim Anderson - Bank of America Mohit Bansal - Wells Fargo Securities Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Terence Flynn - Morgan Stanley Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities David Risinger - Leerink Partners Matt Phipps - William Blair Steve Scala - Cowen Kripa Devarakonda - Truist Securities Olivia Brayer - Cantor Fitzgerald James Shin - Deutsche Bank Sean McCutchen - Raymond James Alexandria Hammond - Wolfe Research Operator Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

News image

BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.

News image

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Thursday.

News image

Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 Earnings

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News image

Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

News image

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

On Thursday, Bristol Myers Squibb & Co BMY posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion.

News image

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth.  The company also issued a full-year 2025 guidance that fell short of Wall Street's expectations, as some of the company's older drugs face competition from cheaper generics.

News image

Trade Tracker: Josh Brown buys Bristol-Myers

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's buying Bristol-Myers at these levels.

News image

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.

News image

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.

News image

Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock.

News image

What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 Earnings

Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

News image

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.

News image

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.

News image

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

News image

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo plus Yervoy as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced HCC.

News image

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.

News image

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News image

Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

10 Undervalued Dividend Growth Stocks: January 2025

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.

News image

3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%.

News image

Bristol-Myers Squibb Earnings

This section highlights Bristol-Myers Squibb's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 24, 2025
Time: Before Market
Est. EPS: $1.66
Status: Unconfirmed

Last Earnings Results

Date: February 06, 2025
EPS: $1.67
Est. EPS: $1.47
Revenue: $12.34B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-06 $1.47 $1.67
Read Transcript Q3 2024 2024-10-31 $1.49 $1.80
Read Transcript Q2 2024 2024-07-26 $1.62 $2.07
Read Transcript Q1 2024 2024-04-25 $-4.41 $-4.40
Read Transcript Q4 2023 2024-02-02 $1.52 $1.70
Read Transcript Q3 2023 2023-10-26 $1.76 $2.00
Read Transcript Q2 2023 2023-07-27 $1.99 $1.75
Read Transcript Q1 2023 2023-04-27 $1.98 $2.05

Financial Statements

Access annual & quarterly financial statements for Bristol-Myers Squibb, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $48.30B $45.01B $46.16B $46.38B $42.52B
Cost of Revenue $- $10.69B $10.14B $9.94B $11.77B
Gross Profit $48.30B $34.31B $36.02B $36.45B $30.75B
Gross Profit Ratio 100.00% 76.24% 78.04% 78.57% 72.31%
Research and Development Expenses $11.16B $9.30B $9.51B $10.20B $11.14B
General and Administrative Expenses $- $6.28B $- $- $-
Selling and Marketing Expenses $- $1.40B $7.81B $7.69B $7.66B
Selling General and Administrative Expenses $8.41B $7.77B $7.81B $7.69B $7.66B
Other Expenses $- $- $9.60B $10.02B $9.76B
Operating Expenses $19.57B $17.89B $26.92B $27.91B $28.57B
Cost and Expenses $19.57B $28.41B $37.05B $37.85B $40.34B
Interest Income $- $- $- $- $-
Interest Expense $- $1.17B $1.23B $1.33B $1.42B
Depreciation and Amortization $- $9.81B $10.29B $10.76B $10.49B
EBITDA $- $19.42B $19.23B $20.19B $5.04B
EBITDA Ratio 0.00% 43.14% 43.16% 43.51% 34.85%
Operating Income $28.73B $17.24B $10.33B $10.16B $5.13B
Operating Income Ratio 59.48% 38.31% 22.37% 21.90% 12.06%
Total Other Income Expenses Net $-37.11B $-8.80B $-10.64B $-9.30B $-7.42B
Income Before Tax $-8.38B $8.44B $7.71B $8.10B $-6.87B
Income Before Tax Ratio -17.35% 18.75% 16.71% 17.46% -16.16%
Income Tax Expense $554.00M $400.00M $1.37B $1.08B $2.12B
Net Income $-8.95B $8.03B $6.33B $6.99B $-8.99B
Net Income Ratio -18.53% 17.83% 13.71% 15.08% -21.16%
EPS $-4.41 $3.88 $2.97 $3.15 $-3.98
EPS Diluted $-4.41 $3.86 $2.95 $3.12 $-3.98
Weighted Average Shares Outstanding 2.03B 2.07B 2.13B 2.22B 2.26B
Weighted Average Shares Outstanding Diluted 2.03B 2.08B 2.15B 2.25B 2.26B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Revenue $11.89B $12.20B $11.87B $11.48B $10.97B $11.23B $11.34B $11.41B $11.22B $11.89B $11.65B $11.98B $11.62B $11.70B $11.07B $11.07B $10.54B $10.13B $10.78B $7.95B
Cost of Revenue $2.96B $5.40B $2.93B $2.75B $2.51B $2.88B $2.57B $2.59B $2.35B $2.72B $2.47B $2.36B $2.29B $2.45B $2.84B $2.91B $2.50B $2.70B $3.66B $2.49B
Gross Profit $8.94B $6.80B $8.93B $8.73B $8.46B $8.35B $8.77B $8.81B $8.87B $9.17B $9.18B $9.63B $9.33B $9.25B $8.23B $8.16B $8.04B $7.43B $7.12B $5.45B
Gross Profit Ratio 75.13% 55.74% 75.29% 76.08% 77.15% 74.38% 77.37% 77.27% 79.02% 77.12% 78.79% 80.34% 80.29% 79.05% 74.34% 73.71% 76.26% 73.35% 66.03% 68.63%
Research and Development Expenses $2.37B $2.29B $2.69B $2.48B $2.24B $2.26B $2.32B $2.51B $2.42B $2.32B $2.26B $2.52B $3.25B $3.27B $2.23B $3.75B $2.50B $2.52B $2.37B $2.10B
General and Administrative Expenses $- $- $- $673.00M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling and Marketing Expenses $1.98B $- $2.37B $1.40B $2.00B $- $1.76B $2.27B $1.93B $- $- $2.35B $1.79B $- $1.67B $2.72B $1.71B $1.63B $1.61B $1.73B
Selling General and Administrative Expenses $1.98B $1.92B $2.37B $2.07B $2.00B $1.93B $1.76B $2.27B $1.93B $1.79B $1.83B $2.35B $1.79B $1.88B $1.67B $2.72B $1.71B $1.63B $1.61B $1.73B
Other Expenses $- $458.00M $401.00M $-272.00M $565.00M $526.00M $2.26B $2.34B $2.42B $470.00M $467.00M $164.00M $443.00M $435.00M $394.00M $472.00M $398.00M $395.00M $459.00M $-94.00M
Operating Expenses $8.94B $4.22B $7.42B $6.83B $4.25B $6.45B $6.34B $7.12B $6.77B $6.53B $6.51B $7.29B $7.58B $7.70B $6.40B $9.00B $6.70B $6.54B $6.34B $4.89B
Cost and Expenses $9.60B $9.62B $10.35B $9.57B $6.75B $9.32B $8.90B $9.71B $9.12B $9.24B $8.98B $9.64B $9.88B $10.15B $9.24B $11.91B $9.20B $9.24B $10.00B $7.38B
Interest Income $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Interest Expense $505.00M $521.00M $425.00M $316.00M $280.00M $282.00M $288.00M $294.00M $299.00M $313.00M $326.00M $323.00M $328.00M $330.00M $353.00M $355.00M $346.00M $357.00M $362.00M $279.00M
Depreciation and Amortization $2.59B $2.56B $2.56B $2.46B $2.45B $2.45B $2.45B $2.50B $2.65B $2.54B $2.65B $2.64B $2.74B $2.64B $2.73B $2.53B $2.65B $2.56B $2.48B $1.06B
EBITDA $4.77B $4.37B $-8.54B $4.45B $4.85B $4.59B $5.50B $4.65B $5.08B $5.36B $5.50B $4.82B $5.48B $5.32B $4.98B $-7.36B $5.24B $4.63B $2.53B $1.40B
EBITDA Ratio 40.14% 42.17% 37.48% 36.14% 38.44% 41.21% 44.95% 41.33% 47.25% 45.32% 43.58% 41.41% 46.31% 40.00% 49.59% 24.06% 44.01% 46.03% 31.35% 22.88%
Operating Income $2.17B $2.58B $3.87B $1.68B $4.21B $4.16B $2.84B $2.37B $2.71B $2.82B $2.49B $2.55B $2.66B $2.13B $2.82B $137.00M $1.98B $2.10B $903.00M $756.00M
Operating Income Ratio 18.26% 21.18% 32.63% 14.67% 38.44% 37.04% 25.05% 20.79% 24.18% 23.74% 21.39% 21.24% 22.85% 18.23% 25.49% 1.24% 18.82% 20.77% 8.38% 9.52%
Total Other Income Expenses Net $-496.00M $-1.30B $-2.86B $-1.95B $-2.08B $-2.30B $-1.90B $-2.21B $-2.31B $-731.00M $-1.02B $-2.82B $-2.14B $-5.00M $-1.81B $-1.66B $-2.04B $-1.65B $-1.23B $-885.00M
Income Before Tax $1.68B $1.29B $-11.52B $1.67B $2.14B $1.86B $2.77B $1.86B $2.21B $1.96B $1.69B $1.86B $2.16B $1.55B $2.53B $-10.45B $2.26B $1.63B $-304.00M $-129.00M
Income Before Tax Ratio 14.09% 10.54% -97.06% 14.59% 19.49% 16.56% 24.43% 16.30% 19.69% 16.47% 14.48% 15.50% 18.56% 13.27% 22.85% -94.43% 21.41% 16.06% -2.82% -1.62%
Income Tax Expense $461.00M $-398.00M $392.00M $-88.00M $203.00M $-218.00M $503.00M $-166.00M $601.00M $529.00M $404.00M $-514.00M $605.00M $492.00M $501.00M $-424.00M $379.00M $1.71B $462.00M $931.00M
Net Income $1.21B $1.68B $-11.91B $1.76B $1.93B $2.07B $2.26B $2.02B $1.61B $1.42B $1.28B $2.37B $1.55B $1.05B $2.02B $-10.03B $1.87B $-85.00M $-775.00M $-1.06B
Net Income Ratio 10.18% 13.77% -100.39% 15.35% 17.58% 18.47% 19.95% 17.73% 14.32% 11.95% 10.97% 19.79% 13.30% 9.01% 18.25% -90.59% 17.76% -0.84% -7.19% -13.29%
EPS $0.60 $0.83 $-5.89 $0.87 $0.94 $0.99 $1.08 $0.96 $0.75 $0.67 $0.60 $1.10 $0.70 $0.47 $0.90 $-4.45 $0.83 $-0.04 $-0.34 $-0.55
EPS Diluted $0.60 $0.83 $-5.89 $0.87 $0.93 $0.99 $1.07 $0.95 $0.75 $0.66 $0.59 $1.07 $0.69 $0.47 $0.89 $-4.45 $0.82 $-0.04 $-0.34 $-0.55
Weighted Average Shares Outstanding 2.03B 2.03B 2.02B 2.03B 2.06B 2.09B 2.10B 2.11B 2.13B 2.13B 2.15B 2.15B 2.22B 2.23B 2.24B 2.25B 2.26B 2.26B 2.26B 1.91B
Weighted Average Shares Outstanding Diluted 2.03B 2.03B 2.02B 2.03B 2.06B 2.10B 2.11B 2.12B 2.15B 2.15B 2.16B 2.22B 2.24B 2.25B 2.27B 2.25B 2.29B 2.26B 2.26B 1.92B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $10.35B $11.46B $9.12B $13.98B $14.55B
Short Term Investments $513.00M $816.00M $130.00M $3.24B $1.28B
Cash and Short Term Investments $10.86B $12.28B $9.12B $13.98B $14.55B
Net Receivables $10.75B $15.26B $13.94B $12.52B $8.50B
Inventory $2.56B $2.66B $2.34B $2.10B $2.07B
Other Current Assets $5.62B $1.56B $1.74B $1.29B $5.58B
Total Current Assets $29.78B $31.77B $27.27B $33.26B $30.19B
Property Plant Equipment Net $7.14B $8.04B $7.47B $6.97B $6.75B
Goodwill $21.72B $21.17B $21.15B $20.50B $20.55B
Intangible Assets $23.31B $27.07B $36.35B $42.77B $53.24B
Goodwill and Intangible Assets $45.03B $48.24B $57.50B $63.28B $73.79B
Long Term Investments $- $2.50B $2.19B $2.71B $4.51B
Tax Assets $4.24B $2.77B $1.34B $1.44B $1.16B
Other Non-Current Assets $6.42B $1.84B $1.04B $1.66B $2.08B
Total Non-Current Assets $62.82B $63.39B $69.55B $76.05B $88.29B
Other Assets $- $- $- $- $-
Total Assets $92.60B $95.16B $96.82B $109.31B $118.48B
Account Payables $3.60B $3.26B $3.04B $2.95B $2.71B
Short Term Debt $2.05B $3.28B $4.40B $5.12B $2.50B
Tax Payables $- $1.37B $942.00M $754.00M $647.00M
Deferred Revenue $- $271.00M $1.34B $3.69B $3.62B
Other Current Liabilities $18.13B $14.35B $13.51B $13.05B $13.22B
Total Current Liabilities $23.77B $22.26B $21.89B $21.87B $19.08B
Long Term Debt $47.60B $38.18B $36.32B $40.48B $49.17B
Deferred Revenue Non-Current $- $300.00M $283.00M $326.00M $357.00M
Deferred Tax Liabilities Non-Current $369.00M $338.00M $2.17B $4.50B $5.41B
Other Non-Current Liabilities $4.47B $4.59B $5.05B $6.13B $6.59B
Total Non-Current Liabilities $52.44B $43.41B $43.81B $51.44B $61.52B
Other Liabilities $- $- $- $- $-
Total Liabilities $76.22B $65.67B $65.70B $73.31B $80.60B
Preferred Stock $- $- $- $- $-
Common Stock $292.00M $292.00M $292.00M $292.00M $292.00M
Retained Earnings $14.91B $28.77B $25.50B $23.82B $21.28B
Accumulated Other Comprehensive Income Loss $-1.24B $-1.55B $-1.28B $-1.27B $-1.84B
Other Total Stockholders Equity $2.37B $1.92B $6.55B $13.10B $18.09B
Total Stockholders Equity $16.34B $29.43B $31.06B $35.95B $37.82B
Total Equity $16.39B $29.48B $31.12B $36.01B $37.88B
Total Liabilities and Stockholders Equity $92.60B $95.16B $96.82B $109.31B $118.48B
Minority Interest $53.00M $55.00M $57.00M $60.00M $60.00M
Total Liabilities and Total Equity $92.60B $95.16B $96.82B $109.31B $118.48B
Total Investments $513.00M $3.31B $2.32B $5.96B $5.79B
Total Debt $49.65B $41.46B $40.72B $45.60B $51.67B
Net Debt $39.30B $30.00B $31.59B $31.62B $37.13B


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Cash and Cash Equivalents $7.89B $6.29B $9.33B $11.46B $7.51B $8.37B $8.99B $9.12B $7.73B $10.75B $12.37B $13.98B $13.54B $11.02B $10.98B $14.55B $19.43B $19.93B $15.82B $12.35B
Short Term Investments $204.00M $360.00M $340.00M $816.00M $171.00M $358.00M $274.00M $130.00M $1.29B $2.52B $2.83B $3.24B $2.28B $2.99B $2.15B $1.28B $1.85B $1.86B $2.50B $3.05B
Cash and Short Term Investments $8.09B $6.66B $9.67B $12.28B $7.68B $8.37B $8.99B $9.12B $9.03B $13.27B $15.20B $13.98B $15.82B $14.02B $13.14B $14.55B $21.28B $21.79B $18.32B $12.35B
Net Receivables $14.89B $15.15B $14.06B $15.26B $15.65B $15.06B $13.40B $13.94B $13.24B $12.54B $11.10B $12.52B $11.74B $11.28B $8.66B $8.50B $8.06B $7.86B $8.29B $7.68B
Inventory $3.33B $3.08B $2.98B $2.66B $2.44B $2.36B $2.60B $2.34B $2.07B $2.14B $2.10B $2.10B $2.16B $2.14B $1.95B $2.07B $1.95B $2.38B $2.84B $4.29B
Other Current Assets $1.75B $2.01B $1.95B $1.56B $1.86B $1.92B $1.75B $1.74B $2.46B $2.24B $1.72B $1.29B $1.72B $1.73B $3.36B $5.58B $2.98B $2.31B $2.40B $1.98B
Total Current Assets $28.07B $26.89B $28.67B $31.77B $27.63B $28.07B $27.09B $27.27B $26.80B $30.19B $30.12B $33.26B $31.44B $29.16B $27.11B $30.19B $34.28B $34.34B $31.85B $29.35B
Property Plant Equipment Net $8.25B $8.16B $8.19B $8.04B $7.85B $7.63B $7.61B $7.47B $6.92B $6.81B $6.94B $6.97B $6.83B $6.80B $6.61B $6.75B $6.46B $5.78B $6.11B $6.25B
Goodwill $21.75B $21.73B $21.74B $21.17B $21.15B $21.16B $21.16B $21.15B $21.11B $20.45B $20.50B $20.50B $20.52B $20.53B $20.52B $20.55B $20.52B $20.58B $22.45B $22.49B
Intangible Assets $26.96B $29.84B $33.17B $27.48B $29.38B $31.77B $34.05B $36.35B $38.73B $38.26B $40.42B $42.77B $44.93B $48.06B $50.82B $53.24B $56.70B $59.17B $61.67B $63.97B
Goodwill and Intangible Assets $48.72B $51.57B $54.91B $48.65B $50.52B $52.94B $55.22B $57.50B $59.84B $58.71B $60.92B $63.28B $65.45B $68.59B $71.34B $73.79B $77.22B $79.75B $84.12B $86.46B
Long Term Investments $2.85B $3.00B $2.23B $2.06B $1.88B $1.99B $2.00B $2.19B $1.96B $1.97B $2.19B $2.71B $4.78B $3.77B $4.64B $4.51B $4.66B $4.41B $651.00M $767.00M
Tax Assets $3.61B $3.32B $2.72B $2.77B $1.51B $1.57B $1.32B $1.34B $1.33B $1.34B $1.42B $1.44B $684.00M $650.00M $793.00M $1.16B $913.00M $1.09B $605.00M $510.00M
Other Non-Current Assets $2.17B $1.70B $2.32B $1.87B $1.86B $1.29B $1.05B $1.04B $1.36B $1.34B $1.45B $1.66B $1.70B $1.83B $1.94B $2.08B $2.01B $2.71B $5.95B $6.60B
Total Non-Current Assets $65.59B $67.76B $70.36B $63.39B $63.63B $65.42B $67.19B $69.55B $71.40B $70.17B $72.91B $76.05B $79.45B $81.64B $85.32B $88.29B $91.26B $93.73B $97.43B $100.59B
Other Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $93.67B $94.65B $99.03B $95.16B $91.26B $93.49B $94.28B $96.82B $98.20B $100.36B $103.03B $109.31B $110.89B $110.80B $112.44B $118.48B $125.54B $128.08B $129.28B $129.94B
Account Payables $3.47B $3.75B $3.54B $3.26B $2.81B $3.07B $3.19B $3.04B $2.60B $2.88B $2.94B $2.95B $2.69B $3.61B $2.97B $2.71B $2.44B $2.85B $3.07B $2.44B
Short Term Debt $1.24B $3.71B $6.36B $3.28B $5.62B $3.19B $2.92B $4.40B $2.30B $5.12B $7.69B $5.12B $5.24B $2.83B $1.94B $2.50B $3.72B $4.95B $4.00B $3.48B
Tax Payables $1.49B $1.47B $1.49B $1.37B $1.46B $1.53B $1.21B $942.00M $1.29B $1.14B $930.00M $754.00M $751.00M $638.00M $716.00M $647.00M $686.00M $2.27B $2.00B $1.52B
Deferred Revenue $- $2.69B $3.86B $4.22B $3.87B $3.79B $- $1.34B $1.33B $3.44B $- $1.44B $3.36B $3.01B $3.01B $1.16B $3.18B $4.61B $4.10B $510.00M
Other Current Liabilities $16.44B $14.33B $14.44B $14.35B $13.57B $12.37B $11.76B $13.51B $12.75B $11.77B $11.25B $13.05B $12.78B $11.92B $11.71B $13.22B $13.62B $13.34B $10.17B $10.86B
Total Current Liabilities $22.64B $23.27B $25.82B $22.26B $23.46B $20.15B $19.09B $21.89B $18.93B $20.91B $22.82B $21.87B $21.46B $18.99B $17.33B $19.08B $20.46B $23.42B $19.23B $18.30B
Long Term Debt $50.16B $50.30B $51.05B $38.18B $33.65B $36.00B $36.45B $36.32B $37.81B $37.92B $38.30B $40.48B $40.61B $43.47B $45.33B $49.17B $42.09B $42.56B $43.53B $44.06B
Deferred Revenue Non-Current $247.00M $263.00M $282.00M $300.00M $316.00M $305.00M $308.00M $283.00M $296.00M $307.00M $319.00M $326.00M $340.00M $324.00M $340.00M $357.00M $361.00M $377.00M $394.00M $424.00M
Deferred Tax Liabilities Non-Current $430.00M $461.00M $442.00M $338.00M $399.00M $751.00M $1.57B $2.17B $2.88B $3.03B $3.81B $4.50B $4.96B $4.93B $5.24B $5.41B $5.91B $6.16B $6.53B $6.45B
Other Non-Current Liabilities $3.00B $3.29B $4.89B $4.59B $4.37B $4.25B $4.99B $5.05B $5.54B $5.52B $6.14B $6.13B $6.25B $6.21B $6.53B $6.59B $6.48B $6.41B $9.62B $9.01B
Total Non-Current Liabilities $53.83B $54.31B $56.66B $43.41B $38.74B $41.31B $43.31B $43.81B $46.53B $46.78B $48.57B $51.44B $52.15B $54.93B $57.43B $61.52B $54.84B $55.49B $60.08B $59.94B
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $76.47B $77.58B $82.48B $65.67B $62.20B $61.46B $62.40B $65.70B $65.46B $67.70B $71.39B $73.31B $73.61B $73.92B $74.76B $80.60B $75.31B $78.92B $79.31B $78.25B
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M $292.00M
Retained Earnings $16.10B $16.10B $15.64B $28.77B $28.22B $27.45B $26.57B $25.50B $24.68B $24.22B $23.95B $23.82B $22.62B $22.17B $22.20B $21.28B $32.41B $31.57B $32.67B $34.47B
Accumulated Other Comprehensive Income Loss $-1.47B $-1.46B $-1.40B $-1.55B $-1.29B $-1.39B $-1.37B $-1.28B $-841.00M $-992.00M $-1.23B $-1.27B $-1.42B $-1.52B $-1.54B $-1.84B $-1.70B $-1.56B $-1.55B $-1.52B
Other Total Stockholders Equity $2.22B $2.08B $1.96B $1.92B $1.77B $5.62B $6.33B $6.55B $8.54B $9.08B $8.57B $13.10B $15.72B $15.87B $16.65B $18.09B $19.15B $18.79B $18.50B $18.35B
Total Stockholders Equity $17.14B $17.02B $16.49B $29.43B $29.00B $31.97B $31.82B $31.06B $32.67B $32.60B $31.58B $35.95B $37.21B $36.81B $37.60B $37.82B $50.16B $49.09B $49.91B $51.60B
Total Equity $17.20B $17.07B $16.55B $29.48B $29.06B $32.03B $31.89B $31.12B $32.73B $32.66B $31.64B $36.01B $37.28B $36.87B $37.67B $37.88B $50.23B $49.16B $49.98B $51.70B
Total Liabilities and Stockholders Equity $93.67B $94.65B $99.03B $95.16B $91.26B $93.49B $94.28B $96.82B $98.20B $100.36B $103.03B $109.31B $110.89B $110.80B $112.44B $118.48B $125.54B $128.08B $129.28B $129.94B
Minority Interest $58.00M $54.00M $58.00M $55.00M $64.00M $57.00M $62.00M $57.00M $63.00M $61.00M $65.00M $60.00M $71.00M $66.00M $68.00M $60.00M $72.00M $66.00M $66.00M $100.00M
Total Liabilities and Total Equity $93.67B $94.65B $99.03B $95.16B $91.26B $93.49B $94.28B $96.82B $98.20B $100.36B $103.03B $109.31B $110.89B $110.80B $112.44B $118.48B $125.54B $128.08B $129.28B $129.94B
Total Investments $3.06B $3.36B $340.00M $2.88B $171.00M $358.00M $2.28B $2.32B $3.25B $4.49B $5.01B $5.96B $7.07B $6.76B $6.79B $6.41B $6.51B $6.27B $3.16B $3.81B
Total Debt $51.40B $54.00B $57.41B $41.46B $39.27B $39.19B $39.37B $40.72B $40.11B $43.04B $45.99B $45.60B $45.84B $46.29B $47.27B $51.67B $45.81B $47.51B $47.53B $47.54B
Net Debt $43.51B $47.71B $48.08B $30.00B $31.75B $30.81B $30.38B $31.59B $32.38B $32.29B $33.63B $31.62B $32.30B $35.27B $36.29B $37.13B $26.37B $27.58B $31.71B $35.19B

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-8.93B $8.04B $6.34B $7.01B $-8.99B
Depreciation and Amortization $9.60B $9.76B $10.28B $10.69B $10.38B
Deferred Income Tax $-2.09B $-3.29B $-2.74B $-1.39B $983.00M
Stock Based Compensation $507.00M $518.00M $457.00M $583.00M $779.00M
Change in Working Capital $- $-1.91B $-2.23B $-1.25B $983.00M
Accounts Receivables $264.00M $-995.00M $-663.00M $-2.12B $-2.95B
Inventory $-486.00M $-751.00M $-69.00M $13.00M $2.67B
Accounts Payables $184.00M $198.00M $109.00M $245.00M $188.00M
Other Working Capital $- $-366.00M $-1.61B $606.00M $1.07B
Other Non Cash Items $16.11B $744.00M $955.00M $570.00M $9.92B
Net Cash Provided by Operating Activities $15.19B $13.86B $13.07B $16.21B $14.05B
Investments in Property Plant and Equipment $-1.25B $-1.21B $-1.12B $-973.00M $-753.00M
Acquisitions Net $-21.82B $-260.00M $-2.98B $-862.00M $-12.21B
Purchases of Investments $-769.00M $-1.77B $-3.59B $-5.48B $-4.17B
Sales Maturities of Investments $1.39B $948.00M $6.63B $6.78B $6.28B
Other Investing Activities $1.10B $- $4.34B $2.04B $2.98B
Net Cash Used for Investing Activities $-21.35B $-2.29B $-1.06B $-538.00M $-10.86B
Debt Repayment $- $456.00M $-5.31B $-6.02B $3.93B
Common Stock Issued $- $- $- $- $-
Common Stock Repurchased $- $-5.16B $-8.00B $-6.29B $-1.55B
Dividends Paid $-4.86B $-4.74B $-4.63B $-4.40B $-4.08B
Other Financing Activities $9.99B $27.00M $984.00M $481.00M $542.00M
Net Cash Used Provided by Financing Activities $5.13B $-9.42B $-16.96B $-16.22B $-1.15B
Effect of Forex Changes on Cash $-137.00M $45.00M $-33.00M $-102.00M $111.00M
Net Change in Cash $-1.17B $2.19B $-4.99B $-657.00M $2.15B
Cash at End of Period $10.35B $11.52B $9.32B $14.32B $14.97B
Cash at Beginning of Period $11.52B $9.32B $14.32B $14.97B $12.82B
Operating Cash Flow $15.19B $13.86B $13.07B $16.21B $14.05B
Capital Expenditure $-1.25B $-1.21B $-1.12B $-973.00M $-753.00M
Free Cash Flow $13.94B $12.65B $11.95B $15.23B $13.30B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $1.22B $1.68B $-11.91B $1.76B $1.93B $2.08B $2.27B $2.02B $1.61B $1.43B $1.28B $2.37B $1.55B $1.06B $2.03B $-10.03B $1.88B $-80.00M $-766.00M $-1.06B
Depreciation and Amortization $2.59B $2.56B $2.53B $2.46B $2.44B $2.43B $2.43B $2.52B $2.59B $2.58B $2.58B $2.58B $2.73B $2.71B $2.67B $2.69B $2.65B $2.56B $2.48B $1.24B
Deferred Income Tax $-256.00M $-331.00M $-711.00M $-1.33B $-327.00M $-1.09B $-548.00M $-624.00M $-645.00M $-782.00M $-687.00M $-1.27B $-32.00M $-163.00M $68.00M $-436.00M $54.00M $1.42B $-53.00M $-337.00M
Stock Based Compensation $129.00M $125.00M $133.00M $127.00M $132.00M $137.00M $122.00M $119.00M $115.00M $116.00M $107.00M $133.00M $142.00M $157.00M $151.00M $171.00M $185.00M $213.00M $210.00M $284.00M
Change in Working Capital $1.71B $-2.37B $198.00M $855.00M $291.00M $-1.70B $-1.36B $-458.00M $164.00M $-1.57B $-362.00M $-56.00M $650.00M $-1.41B $-434.00M $-154.00M $-1.29B $1.14B $1.28B $1.84B
Accounts Receivables $661.00M $-1.02B $479.00M $536.00M $-659.00M $-2.18B $-175.00M $-106.00M $-557.00M $-669.00M $786.00M $-646.00M $-306.00M $-1.72B $67.00M $-646.00M $-2.45B $502.00M $-743.00M $752.00M
Inventory $-218.00M $-225.00M $-218.00M $-197.00M $-256.00M $-16.00M $-282.00M $-41.00M $-16.00M $-13.00M $1.00M $-128.00M $30.00M $5.00M $106.00M $101.00M $481.00M $642.00M $1.45B $470.00M
Accounts Payables $-374.00M $-259.00M $300.00M $444.00M $-268.00M $-165.00M $187.00M $405.00M $-300.00M $-19.00M $23.00M $226.00M $-139.00M $-145.00M $303.00M $132.00M $-424.00M $-223.00M $703.00M $181.00M
Other Working Capital $1.64B $-868.00M $-1.27B $72.00M $1.47B $665.00M $-1.09B $-716.00M $1.04B $329.00M $-1.17B $492.00M $1.06B $442.00M $-910.00M $259.00M $1.10B $220.00M $-126.00M $442.00M
Other Non Cash Items $204.00M $7.41B $12.97B $371.00M $286.00M $27.00M $60.00M $-277.00M $-143.00M $370.00M $887.00M $295.00M $227.00M $706.00M $-658.00M $11.43B $-1.27B $-981.00M $744.00M $70.00M
Net Cash Provided by Operating Activities $5.59B $2.33B $2.83B $4.25B $4.75B $1.89B $2.97B $3.31B $3.69B $2.26B $3.81B $4.06B $5.27B $3.06B $3.82B $3.67B $2.22B $4.27B $3.89B $2.04B
Investments in Property Plant and Equipment $-324.00M $-262.00M $-284.00M $-330.00M $-342.00M $-259.00M $-278.00M $-346.00M $-247.00M $-272.00M $-253.00M $-320.00M $-270.00M $-210.00M $-173.00M $-283.00M $-153.00M $-131.00M $-186.00M $-251.00M
Acquisitions Net $-859.00M $-1.10B $-19.81B $-340.00M $-79.00M $10.00M $149.00M $374.00M $-3.04B $-275.00M $-40.00M $26.00M $-869.00M $-569.00M $550.00M $-12.34B $-41.00M $-10.00M $180.00M $-10.81B
Purchases of Investments $-40.00M $-84.00M $-274.00M $-717.00M $-502.00M $-355.00M $-200.00M $-26.00M $-274.00M $-1.58B $-1.71B $-2.07B $-1.06B $-1.04B $-1.30B $-1.02B $-1.19B $-1.22B $-735.00M $-2.32B
Sales Maturities of Investments $238.00M $130.00M $752.00M $41.00M $513.00M $275.00M $119.00M $1.21B $1.48B $1.84B $2.10B $2.77B $1.23B $2.00B $782.00M $1.52B $1.22B $2.14B $1.39B $1.34B
Other Investing Activities $766.00M $316.00M $241.00M $-435.00M $258.00M $114.00M $146.00M $1.68B $1.43B $450.00M $790.00M $873.00M $351.00M $756.00M $65.00M $819.00M $231.00M $1.06B $864.00M $12.79B
Net Cash Used for Investing Activities $-219.00M $-1.32B $-19.62B $-1.35B $-410.00M $-329.00M $-210.00M $1.21B $-2.08B $-289.00M $95.00M $401.00M $-976.00M $180.00M $-143.00M $-12.13B $-165.00M $780.00M $653.00M $-12.04B
Debt Repayment $-2.65B $-2.80B $15.95B $2.10B $-10.00M $-124.00M $-1.51B $136.00M $-2.86B $-2.79B $199.00M $-114.00M $-361.00M $-1.12B $-4.52B $5.69B $-1.74B $-48.00M $- $4.00M
Common Stock Issued $- $- $- $-10.00M $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock Repurchased $- $- $- $- $-4.00B $-905.00M $-250.00M $-2.42B $-585.00M $- $-5.00B $-2.75B $-525.00M $-1.24B $-1.77B $-1.47B $- $- $-81.00M $-7.00B
Dividends Paid $-1.22B $-1.22B $-1.21B $-1.16B $-1.19B $-1.20B $-1.20B $-1.15B $-1.15B $-1.15B $-1.19B $-1.10B $-1.09B $-1.10B $-1.11B $-1.02B $-1.02B $-1.02B $-1.02B $-668.00M
Other Financing Activities $16.00M $-6.00M $-97.00M $25.00M $41.00M $53.00M $-92.00M $179.00M $53.00M $419.00M $333.00M $-3.00M $196.00M $276.00M $110.00M $277.00M $171.00M $76.00M $44.00M $-13.00M
Net Cash Used Provided by Financing Activities $-3.85B $-4.02B $14.64B $967.00M $-5.16B $-2.17B $-3.05B $-3.25B $-4.54B $-3.52B $-5.65B $-3.97B $-1.78B $-3.18B $-7.29B $3.48B $-2.59B $-993.00M $-1.05B $-7.68B
Effect of Forex Changes on Cash $77.00M $-22.00M $-45.00M $78.00M $-38.00M $-8.00M $13.00M $95.00M $-66.00M $-71.00M $9.00M $-54.00M $-28.00M $18.00M $-38.00M $87.00M $31.00M $60.00M $-67.00M $6.00M
Net Change in Cash $1.60B $-3.04B $-2.19B $3.95B $-857.00M $-623.00M $-277.00M $1.37B $-3.00B $-1.62B $-1.74B $437.00M $2.48B $76.00M $-3.65B $-4.89B $-502.00M $4.12B $3.43B $-17.67B
Cash at End of Period $7.89B $6.29B $9.33B $11.52B $7.57B $8.43B $9.05B $9.32B $7.96B $10.96B $12.58B $14.32B $13.88B $11.40B $11.32B $14.97B $19.86B $20.36B $16.25B $12.82B
Cash at Beginning of Period $6.29B $9.33B $11.52B $7.57B $8.43B $9.05B $9.32B $7.96B $10.96B $12.58B $14.32B $13.88B $11.40B $11.32B $14.97B $19.86B $20.36B $16.25B $12.82B $30.49B
Operating Cash Flow $5.59B $2.33B $2.83B $4.25B $4.75B $1.89B $2.97B $3.31B $3.69B $2.26B $3.81B $4.06B $5.27B $3.06B $3.82B $3.67B $2.22B $4.27B $3.89B $2.04B
Capital Expenditure $-324.00M $-262.00M $-284.00M $-330.00M $-342.00M $-259.00M $-278.00M $-346.00M $-247.00M $-272.00M $-253.00M $-320.00M $-270.00M $-210.00M $-173.00M $-283.00M $-153.00M $-131.00M $-186.00M $-251.00M
Free Cash Flow $5.27B $2.06B $2.55B $3.92B $4.41B $1.63B $2.69B $2.96B $3.44B $1.99B $3.56B $3.74B $5.00B $2.85B $3.65B $3.39B $2.07B $4.14B $3.71B $1.79B


Bristol-Myers Squibb Stock Forecast

Analyst ratings, price targets, and earnings estimates for BMY.

BMY Analyst Ratings

Hold

Buy
7
Hold
12
Sell
1

Based on 20 analysts in the past 3 months

BMY Stock 12 Month Forecast

$53.43

▼ (-0.87% Downside)
Highest Price Target
$ (0.0%)
Average Price Target
$53.43 (-0.9%)
Lowest Price Target
$ (0.0%)

Based on 7 analysts in the last year

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $47.32B
Average $45.84B
Low $45.16B
17 analysts
Net Income Estimates
High $14.66B
Average $13.81B
Low $12.95B
17 analysts
EPS Estimates
High $7.22
Average $6.81
Low $6.38
14 analysts
Revenue Estimates
High $45.77B
Average $43.18B
Low $41.19B
24 analysts
Net Income Estimates
High $14.17B
Average $12.39B
Low $10.62B
24 analysts
EPS Estimates
High $6.97
Average $6.16
Low $5.23
17 analysts
Revenue Estimates
High $43.04B
Average $42.98B
Low $42.93B
19 analysts
Net Income Estimates
High $15.97B
Average $9.87B
Low $7.82B
19 analysts
EPS Estimates
High $7.86
Average $6.05
Low $3.85
10 analysts
Revenue Estimates
High $41.93B
Average $40.46B
Low $39.52B
8 analysts
Net Income Estimates
High $12.72B
Average $12.15B
Low $11.78B
8 analysts
EPS Estimates
High $6.26
Average $5.98
Low $5.80
5 analysts
Revenue Estimates
High $39.74B
Average $38.34B
Low $37.46B
9 analysts
Net Income Estimates
High $12.33B
Average $11.77B
Low $11.42B
9 analysts
EPS Estimates
High $6.07
Average $5.80
Low $5.62
4 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Nov 12, 2024 Evan Seigerman BMO Capital $61.00 $56.23 8.5%
Nov 01, 2024 Evan David Seigerman BMO Capital $57.00 $54.32 4.9%
Sep 23, 2024 Evan David Seigerman BMO Capital $48.00 $49.56 -3.1%
Jul 29, 2024 Chris Shibutani Goldman Sachs $57.00 $50.55 12.8%
Jul 29, 2024 Carter Gould Barclays $41.00 $50.45 -18.7%
Jul 12, 2024 Trung Huynh UBS $43.00 $40.68 5.7%
May 16, 2024 Steve Scala Cowen & Co. $67.00 $44.11 51.9%
Jan 30, 2024 James Shin Deutsche Bank $55.00 $49.87 10.3%
Nov 27, 2023 Evan Seigerman BMO Capital $60.00 $49.76 20.6%
Oct 12, 2023 David Risinger Leerink Partners $66.00 $56.25 17.3%

Bristol-Myers Squibb Dividends

Explore Bristol-Myers Squibb's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

4.24%

Dividend Payout Ratio

-54.35%

Dividend Paid & Capex Coverage Ratio

2.49x



Bristol-Myers Squibb Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.62 $0.62 January 03, 2025 January 03, 2025 February 03, 2025 December 11, 2024
$0.6 $0.6 October 04, 2024 October 04, 2024 November 01, 2024 September 10, 2024
$0.6 $0.6 July 05, 2024 July 05, 2024 August 01, 2024 June 18, 2024
$0.6 $0.6 April 04, 2024 April 05, 2024 May 01, 2024 March 01, 2024
$0.6 $0.6 January 04, 2024 January 05, 2024 February 01, 2024 December 06, 2023
$0.57 $0.57 October 05, 2023 October 06, 2023 November 01, 2023 September 20, 2023
$0.57 $0.57 July 06, 2023 July 07, 2023 August 01, 2023 June 14, 2023
$0.57 $0.57 April 06, 2023 April 10, 2023 May 01, 2023 March 03, 2023
$0.57 $0.57 January 05, 2023 January 06, 2023 February 01, 2023 December 08, 2022
$0.54 $0.54 October 06, 2022 October 07, 2022 November 01, 2022 September 14, 2022
$0.54 $0.54 June 30, 2022 July 01, 2022 August 01, 2022 June 15, 2022
$0.54 $0.54 March 31, 2022 April 01, 2022 May 02, 2022 March 01, 2022
$0.54 $0.54 January 06, 2022 January 07, 2022 February 01, 2022 December 13, 2021
$0.49 $0.49 September 30, 2021 October 01, 2021 November 01, 2021 September 09, 2021
$0.49 $0.49 July 01, 2021 July 02, 2021 August 02, 2021 June 17, 2021
$0.49 $0.49 March 31, 2021 April 01, 2021 May 03, 2021 March 01, 2021
$0.49 $0.49 December 31, 2020 January 04, 2021 February 01, 2021 December 10, 2020
$0.45 $0.45 October 01, 2020 October 02, 2020 November 02, 2020 September 10, 2020
$0.45 $0.45 July 02, 2020 July 06, 2020 August 03, 2020 June 11, 2020
$0.45 $0.45 April 02, 2020 April 03, 2020 May 01, 2020 March 02, 2020

Peers: Drug Manufacturers - General

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
ABBV Logo
AbbVie Inc.
ABBV
$340.83B $192.87 $2.75 $56.34 $26.45
MRK Logo
Merck & Co., Inc.
MRK
$209.99B $83.01 $0.14 $778.71 $7.56
GILD Logo
Gilead Sciences, Inc.
GILD
$129.71B $104.08 $0.38 $239.97 $0.00
JNJ Logo
Johnson & Johnson
JNJ
$375.95B $156.15 $5.84 $24.53 $27385.90
LLY Logo
Eli Lilly and Company
LLY
$801.48B $844.27 $11.71 $65.93 $48.75
PFE Logo
Pfizer Inc.
PFE
$144.68B $25.53 $1.42 $18.71 $1.62
AMGN Logo
Amgen Inc.
AMGN
$156.51B $291.16 $7.56 $34.48 $23.99
BIIB Logo
Biogen Inc.
BIIB
$20.01B $137.33 $11.20 $13.65 $1.33
Current Reports (8-K)
Ownership